Renaissance Technologies LLC Sells 211,386 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Renaissance Technologies LLC reduced its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 36.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 363,400 shares of the company's stock after selling 211,386 shares during the quarter. Renaissance Technologies LLC owned 0.43% of Verve Therapeutics worth $2,050,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Barclays PLC grew its holdings in shares of Verve Therapeutics by 139.8% during the 3rd quarter. Barclays PLC now owns 222,919 shares of the company's stock valued at $1,079,000 after purchasing an additional 129,944 shares during the last quarter. Norges Bank bought a new stake in shares of Verve Therapeutics during the fourth quarter worth $441,000. Nisa Investment Advisors LLC increased its holdings in shares of Verve Therapeutics by 465.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company's stock worth $241,000 after buying an additional 35,214 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after acquiring an additional 3,964 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Verve Therapeutics by 1.9% during the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock valued at $627,000 after acquiring an additional 2,093 shares in the last quarter. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Price Performance

Shares of VERV traded down $0.27 during trading hours on Tuesday, hitting $5.46. 2,143,933 shares of the stock were exchanged, compared to its average volume of 1,770,230. The firm has a market capitalization of $484.83 million, a P/E ratio of -2.22 and a beta of 1.86. Verve Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $9.31. The business has a 50-day moving average of $5.30 and a 200-day moving average of $5.96.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. As a group, analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Canaccord Genuity Group upped their target price on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Royal Bank of Canada dropped their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Finally, HC Wainwright boosted their price objective on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, April 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Verve Therapeutics has an average rating of "Buy" and an average price target of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.